Pharma BD Deal Intelligence
Sanofi SA / Novavax Inc.
2024 · Licensing/Option · $1.2B · Complete
Announcement Sentiment
88
Strongly positive
Outcome Score
51
Mixed — partial payoff, real shortfalls.
Sanofi licensed Novavax's adjuvanted COVID-19 vaccine for exclusive commercialization rights, paying $500M upfront in a deal worth up to $1.2B.
Key facts
- Announced May 10, 2024
- Closed May 10, 2024
- Deal value $1.2B
- Deal type Licensing/Option
- Therapeutic area Infectious Disease, Vaccines
- Indications COVID-19
- Key assets Adjuvanted COVID-19 vaccine
- Mechanism Protein subunit vaccine with adjuvant
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals